Floatz logo

Cetuximab

KRAS G12C Mutation

Second Affiliated Hospital, School of Medicine, Zhejiang Universitymonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the KRAS G12C Mutation cohort.

Asset / SponsorPhaseRating
ibi351
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2CCC
PANITUMUMAB
Federation Francophone de Cancerologie Digestive
Phase 2CCC
Fulzerasib
Jianxing He
Phase 2CCC
Paxalisib
Alliance for Clinical Trials in Oncology
Phase 2CCC
Abemaciclib
Alliance for Clinical Trials in Oncology
Phase 2CCC

View all 12 →

Same molecule, other indications

Cetuximab is also rated in:

colon adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
rectal carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →